Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

HIV/AIDs eradication based on targeting the latent virus with potent Prostratin and other analogues that selectively modulate protein kinase C activity


Stanford Reference:

09-143


Abstract


HAART is the current therapy for HIV/AIDS. It stops disease progression for many by reducing active viral loads to undetectable levels. However it requires chronic therapy with associated cost, compliance, resistance and exposure issues. Cessation of HAART leads to viral rebound. Viral rebound is caused by the slow conversion of genomically encoded latent virus in cellular reservoirs into the active virus. Prostratin, discovered as a traditional medicine used by healers in Western Samoa, has been found to target latent virus, purging it from its cellular reservoirs.

Stanford researchers have now developed the first synthesis of prostratin that can be used to supply clinical trials and, importantly, using this approach they have now prepared new analogs that are a 1000-fold more potent than prostratin. The new agents have shown activity in cellular models of disease, including selective modulation of PKC signaling that is coupled to latent virus induction. Significantly, these agents have been shown to work in ex vivo studies using blood draws from AIDS patients on suppressive HAART therapy. Prostatin itself has been used in humans in traditional medicine practices in Western Samoa. Animal studies are in progress. These and related agents in the Stanford collection provide the basis for a first-in-class approach to eradication of HIV/AIDS.


Applications


  • Eradication of HIV/AIDS by eliminating latent viral reservoirs in combination with HAART therapy
  • Targeting latent viruses associated with other diseases
  • Other therapeutic indications based on selective PKC modulation include cancer, Alzheimer’s, neuropathic pain, cardiovascular disease, etc.

Advantages


  • First-in-class opportunity to target latent disease, the cause of viral rebound and thus chronic therapy
  • Would eliminate the need for chronic therapy
  • Would avoid compliance issues by eliminating the need for chronic therapy
  • Would minimize cost, as the treatment would eliminate the cause of rebound
  • Already “tested” in humans as traditional medicine regimen

Publications



Related Web Links



Innovators & Portfolio


  • Pierre-Luc Boudreault   
  • Brian DeChristopher   
  • Dennis Fournogerakis   
  • Carolyn Gauntlett   
  • Lars Heumann   
  • Rainer Kramer   
  • Elizabeth Mieluli   
  • Adam Schrier   
  • Paul Wender   more technologies from Paul Wender »

Patent Status



Date Released

 3/1/2016
 

Licensing Contact


Irit Gal, Senior Licensing Associate
650-723-1586 (Business)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-168 Peptides That Modulate Interaction Between PKC and RACK

more technologies »

Related Keywords


adjuvant   drug development   HIV/AIDS   AIDS   therapeutic: antiviral   therapeutic: drug design   therapeutic: HIV   therapeutic: pro-drug   therapeutic: small molecule   HIV   immune disease therapeutics   small molecule production   Small Molecule Therapeutics   Therapeutic formulations   therapeutic: autoimmune diseases   therapeutic: cell signalling   therapeutic: immunotherapy   therapeutic: infectious disease   top pharma companies   PKC   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
93-168 Peptides That Modulate Interaction Between PKC and RACK

Recently Viewed...
S09-143 HIV/AIDs eradication based on targeting the latent virus with potent Prostratin and other analogues that selectively modulate protein kinase C activity